Research programme: toll-like receptor inhibitors - Dynavax Technologies

Drug Profile

Research programme: toll-like receptor inhibitors - Dynavax Technologies

Alternative Names: IRS-954

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; GlaxoSmithKline
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 08 Mar 2016 Dynavax Technologies has patent protection for its TLR agonists and antagonists in USA (Dynavax Technology, Form 10-K, March 2016)
  • 28 Nov 2014 Dynavax Technologies regains full rights to all TLR 7/9 inhibitors for all indications
  • 27 Oct 2011 Preclinical development is ongoing for Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top